Ticagrelor or prasugrel vs. clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention for myocardial infarction

Figures

• 

  Figure 1. Flow chart illustrating selection of the study population. MI, myocardial infarction; P2Y12i, P2Y12 inhibitor; PCI, percutaneous coronary intervention; AF, atrial fibrillation; OAC, oral anticoagulation; DNPR, the Danish National Patient Registry.

• 

  Figure 2. Standardized absolute risk of primary efficacy (major adverse cardiovascular events) and safety (bleeding events requiring hospitalizations) outcomes at 12 months stratified by treatment group (clopidogrel vs. ticagrelor or prasugrel). C, clopidogrel; T/P, ticagrelor/prasugrel.

• 

  Figure 3. Standardized relative risk of primary efficacy (major adverse cardiovascular events) and safety (bleeding events requiring hospitalizations) outcomes at 12 months comparing the two treatment groups (ticagrelor or prasugrel vs. clopidogrel).

• 

  Figure 4. Standardized relative risk of the secondary outcomes comparing the two treatment groups (ticagrelor or prasugrel vs. clopidogrel).